CLINICAL USE


Prophylaxis and treatment of acute hyperuricaemia with initial chemotherapy for haematological malignancy

DOSE IN NORMAL RENAL FUNCTION

200 mcg/kg once daily for up to 7 days

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :34 000
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :0
  • %Excreted unchanged in urine &nbsp &nbsp : 0

  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :0.11–0.127

  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :19/–

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in normal renal function

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unlikely to be dialysed. Dose as in normal renal function
  • HDF/high flux &nbsp :Unlikely to be dialysed. Dose as in normal renal function
  • CAV/VVHD &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • None known

    ADMINISTRATION

    Reconstition

    With solvent provided

    Route

    IV

    Rate of Administration

    Over 30 minutes

    Comments

    Add appropriate volume to 50 mL sodium chloride 0.9%

    OTHER INFORMATION

    Renal elimination of rasburicase is considered to be a minor pathway for rasburicase clearanceRasburicase is a protein; it is expected that metabolic degradation will follow the pathways of other proteins, i.e. peptide hydrolysisAfter infusion of rasburicase at a dose of 0.20 mg/kg/day, steady state is achieved at day 2–3.
    Tags:

    • Related News

    ffddfd

    Hyperlipidemia